Vera Therapeutics, Inc. (VERA) - Stock Analysis
Last updated: Jul 6, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Near-term binary catalyst with FDA priority review for atacicept in IgA nephropathy and PDUFA date on 2026-07-07. Shares are up about 35% over 20 trading days, supported by biotech rotation and focused regulatory attention.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Ongoing cash burn ⢠No revenue VERA has a very strong liquidity position and low leverage, but persistent losses, heavy cash burn, and no revenue mean its valuation is driven by future execution rather than current fundamentals.
Price Behavior
Key Price Behavior Insights: ⢠Higher lows ⢠Support holding ⢠Overbought pullback Support Level: $38.20â$39.51 Resistance Level: $43.15 Over the last month, VERA has staged a strong bullish reversal with higher lows and rising momentum, but it is now pulling back from $43.15 and may need to consolidate above $40.50â$41.20 to keep the uptrend intact.
Sentiment & News
Key News Insights: ⢠Near-term catalyst ⢠Binary outcomes ⢠Repeated coverage VERA is attracting repeated attention as an event-driven biotech name tied to potential near-term clinical or FDA catalysts, though no new company-specific updates were disclosed. ŕ´ ŕ´
AI Summary
VERA has evolved into a near-term FDA catalyst with enough cash and investments to fund the path to commercialization, but the stock already prices in success, so the key investment call is whether atacicept can clear approval and launch cleanly enough to offset the still-binary, single-asset and cash-burn risks.
Description
Vera Therapeutics is a clinical-stage biotech company developing therapies for serious immune-mediated diseases in the United States. Its lead candidate, atacicept, is a subcutaneously administered fusion protein in Phase IIb testing for immunoglobulin A nephropathy, and the company also has MAU868, a monoclonal antibody in Phase II for BK viremia. The company was incorporated in 2016 and is based in Brisbane, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 7 | Jul 14 | VERA | Vera Therapeutics, Inc. | Near-term binary catalyst with FDA priority review for atacicept in IgA nephropathy and PDUFA date on 2026-07-07. Shares are up about 35% over 20 trading days, supported by biotech rotation and focused regulatory attention. | Active | +0.0% |